bioAffinity Technologies, Inc. (BIAFW) stock
BIAFWNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 4/3056% below fair value
$0.24+0.00 (0.00%)
Close on Oct 30, 2026Market cap $23.58MP/E –Yield –
bioAffinity Technologies revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
bioAffinity Technologies's revenue for the twelve months ending Jun 30, 2026 was $5.90M, down 23.2% year over year. For fiscal 2025 it was $6.16M, down 34.2% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.16M | -34.2% |
| FY2024 | Dec 31, 2024 | $9.36M | +269.7% |
| FY2023 | Dec 31, 2023 | $2.53M | -63.3% |
| FY2022 | Dec 31, 2022 | $6.90M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.51M | +19.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.35M | -27.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.59M | -27.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.45M | -38.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.27M | -47.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.85M | -23.0% |
| Q4 FY2024 | Dec 31, 2024 | $2.21M | -2.4% |
| Q3 FY2024 | Sep 30, 2024 | $2.35M | +687.4% |
| Q2 FY2024 | Jun 30, 2024 | $2.40M | +12047.4% |
| Q1 FY2024 | Mar 31, 2024 | $2.41M | +33.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.26M | -67.2% |
| Q3 FY2023 | Sep 30, 2023 | $298.48K | +25855.1% |
| Q2 FY2023 | Jun 30, 2023 | $19.74K | +1411.3% |
| Q1 FY2023 | Mar 31, 2023 | $1.81M | – |
| Q4 FY2022 | Dec 31, 2022 | $6.90M | – |
| Q3 FY2022 | Sep 30, 2022 | $1.15K | – |
| Q2 FY2022 | Jun 30, 2022 | $1.31K | – |